Loading...
Market
Will the Phase 3 trial for DengiAll vaccine be completed by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcement from ICMR or Panacea Biotec
Story
ICMR and Panacea Biotec Start Phase 3 Trial for DengiAll, India's First Indigenous Dengue Vaccine
Aug 14, 2024, 12:15 PM
The Indian Council of Medical Research (ICMR) and pharmaceutical company Panacea Biotec have initiated the first-ever Phase 3 clinical trial for a dengue vaccine in India. The indigenous vaccine, named DengiAll, marks a significant advancement in the fight against dengue. The trial began with the administration of the first dose in Rohtak, Haryana, ahead of India's Independence Day 2024. This development comes as dengue cases remain a concern in India, with 289,235 cases and 485 deaths reported in 2023, according to the National Centre for Vector Borne Diseases Control Programme.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
No results announced • 25%